Quinapril with hydrochlorothiazide
Brand names: Accuretic
This is a fixed-dose oral combination of quinapril, an ACE inhibitor, with hydrochlorothiazide, a thiazide diuretic, used for essential hypertension not adequately controlled on quinapril alone.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Quinapril inhibits angiotensin-converting enzyme to lower angiotensin-II-mediated vasoconstriction and aldosterone secretion, while hydrochlorothiazide increases renal sodium and water excretion; the ACE inhibitor offsets diuretic-induced renin-angiotensin activation.
Prescribing in practice
- Avoid in pregnancy because the ACE-inhibitor component is foetotoxic; counsel women of childbearing potential and review contraception.
- ACE inhibitors can cause angioedema requiring permanent withdrawal and a persistent dry cough, while the thiazide adds risks of hyponatraemia, hypokalaemia, hyperuricaemia and glucose intolerance.
- First-dose hypotension, hyperkalaemia and renal impairment can occur, especially with volume depletion, renal artery stenosis or NSAIDs.
Monitoring
Monitor blood pressure, renal function and serum electrolytes including sodium and potassium at baseline and after dose changes.
Counselling the patient
- Seek urgent help for swelling of the face, lips, tongue or throat.
- Report a persistent dry cough so an alternative can be considered.
- Tell your doctor immediately if you become pregnant.
Evidence & guidelines
Combining an ACE inhibitor with a thiazide diuretic is an established step in NICE hypertension management, and the fixed-dose combination supports adherence.
Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines